

GFP licensing statements

GFP Assays

All GFP and Emerald FP Products:

This product is sold under license from Fisher BioImage ApS (formerly BioImage A/S) under patent numbers US 6,172,188, US 6,818,443, US 5,958,713, US 7,314,915, CA 2232727, EP 0815257, EP 851874, JP 3535177 and equivalent patents and patent applications in other countries.

This product is sold under license from Invitrogen IP Holdings Inc (formerly Vertex Pharmaceuticals (San Diego) LLC, formerly Aurora Biosciences Corporation) under patent numbers US 5,625,048, US 5,777,079, US 5,804,387, US 5,968,738, US 5,994,077, US 6,054,321, US 6,066,476, US 6,077,707, US 6,090,919, US 6,124,128, US 6,319,669, US 6,403,374, EP 0804457, JP 3283523 and equivalent patents and patent applications in other countries.

This product is sold under license from Columbia University under patent numbers US 5,491,084 and 6,146,826.

Note: For products containing mutations at position 222 such as the triple GFP mutant (F64L, E222G, S175G) the Invitrogen IP Holdings does not apply. For example, MAPKAP-k2, Rac-1 and PLC-PH Domain products.



NOTE: Where the assay involves a mutation at position 222 then an additional line for the Fisher BioImage ApS statement is required:

This product is sold under license from Fisher BioImage ApS (formerly BioImage A/S) under patent number US 7,001,986 and equivalent patents and patent applications in other countries.

NOTE: Where the assay involves a humanized codon:

This product is sold under license from University of Florida under patent numbers US 5,968,750, US 5,874,304, US 5,795,737, US 6,020,192 and equivalent patents and patent applications in other countries.

NOTE: Where the assay contains a Triple Mutant:

This product is the subject of patent numbers US 6,919,186, US 7,091,317 and EP 1381625 and equivalent patents and patent applications in other countries in the name of GE Healthcare UK Limited.

NOTE: For Akt, SMAD2, STAT3, NFAT-C2, MAPKAP-k2, Rac-1, PLC- PH Domain products:

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

NOTE: Where the assay involves Redistribution:

This product is sold under license from Fisher BioImage ApS (formerly BioImage A/S) under patent numbers US 6,518,021 and EP 0986753 and equivalent patents and patent applications in other countries.

NOTE: Where the assay involves a G2M Cell Cycle Phase Marker:

The G2M Cell Cycle Phase Marker Assay is the subject of patent applications AU 2002326036, CA 2461133, EP 1432819, , JP 4607454 and US 7,235,401 in the name of GE Healthcare UK Limited and Cancer Research Campaign Technology.

NOTE: Where the assay involves a G1S Cell Cycle Phase Marker:

The G1S Cell Cycle Phase Marker assay is the subject of international patent application numbers US 7,612,189 and US 7,745,123 in the name of GE Healthcare UK Limited and Vanderbilt University.

NOTE: Where the assay involves an FYVE domain:

This product is sold under license from Cedars Sinai Medical Centre under patent number US 6,376,174 and equivalent patents and patent applications in other countries.

NOTE: Where the assay involves an STAT3:

This product is sold under license from Osaka University under patent numbers US 5,719,042 and US 5,844,082 and equivalent patents and patent applications in other countries.

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

NOTE: Where the assay involves an NFAT-c1:

This product is sold under license from Leland Stanford Junior University under patent numbers US 5,837,840, US 5,989,810, US 6,171,781, US 6,197,925, US 6,312,899, US 6,352,830, US 6,388,052, US 6,150,099, EP 0722452 and equivalent patents and patent applications in other countries.

NOTE: Where the assay involves an NFAT-RE:

This product is sold under license from Leland Stanford Junior University under patent numbers US 5,837,840, US 5,989,810, US 6,171,781, US 6,197,925, US 6,312,899, US 6,352,830, US 6,388,052, US 6,150,099, EP 0722452 and equivalent patents and patent applications in other countries.

NOTE: Where the assay involves an MADR2/SMAD2:

This product is sold under license from HSC Research and Development Limited Partnership under patent number US 6,017,755 and equivalent patents and patent applications in other countries.

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

NOTE: Where the assay involves the PLC – PH Domain:

For customers wishing to use the assay for screening for potential therapeutic agents, attention is drawn to the existence of US patent number 6,054,280 'Methods for Diagnosis and Treatment of PH Domain Signal Transduction Disorders', issued 25 April 2000 and assigned to Sugen Inc., CA, USA.

This product was developed in collaboration with Fisher BioImage ApS (formerly BioImage A/S).

